home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 11/20/19

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - CRC, CGIX, XXII and PDD among midday movers

Gainers:  Cancer Genetics CGIX  +224% . More news on: Surface Oncology, Inc., Cellectar Biosciences, Inc., Magenta Therapeutics, Inc., Stocks on the move, Read more ...

CLRB - Cellectar Biosciences EPS misses by $0.04

Cellectar Biosciences (NASDAQ: CLRB ): Q3 GAAP EPS of -$0.42 misses by $0.04 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

CLRB - Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

FLORHAM PARK, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quar...

CLRB - Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

FLORHAM PARK, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced Jarrod Longcor, chief busines...
CLRB - Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

FLORHAM PARK, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the ...

CLRB - Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

Data demonstrate phospholipid ether (PLE) molecules ability to target wide range of tumors FLORHAM PARK, N.J., Oct. 15, 2019 (GLOBE NEWSWIRE) --   Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and...

CLRB - Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

FLORHAM PARK, N.J., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the ...
CLRB - Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress

FLORHAM PARK, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced Jarrod Longcor, chief busine...

CLRB - OSTK, NBEV among premarket gainers

AIM ImmunoTech (NYSEMKT: AIM ) +34%  after DoD grant for Ampligen in BMBC. More news on: AIM ImmunoTech Inc., Ideal Power Inc., New Age Beverages Corporation, Stocks on the move, Read more ...

CLRB - Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma

FLORHAM PARK, N.J., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the European Commission h...
Previous 10 Next 10